UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 102

Sortiert nach

Ubrogepant for the Treatment of Migraine

The New England journal of medicine, 2019-12, Vol.381 (23), p.2230-2241

2019

Link zum Volltext

Verfügbarkeit prüfen

Asenapine for the Acute Treatment of Pediatric Manic or Mixed Episode of Bipolar I Disorder

Journal of the American Academy of Child and Adolescent Psychiatry, 2015-12, Vol.54 (12), p.1032-1041

2015

Link zum Volltext

Verfügbarkeit prüfen

A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment

The journal of clinical psychiatry, 2011-03, Vol.72 (3), p.349

2011

Link zum Volltext

Verfügbarkeit prüfen

Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials

BMC psychiatry, 2011-06, Vol.11 (1), p.101-101, Article 101

2011

Link zum Volltext

Verfügbarkeit prüfen

Sollte bereits nach zwei Wochen ein Medikationswechsel erfolgen?

InFo Neurologie & Psychiatrie, 2016-09, Vol.18 (9), p.23-24

Szegedi, Armin

2016

Link zum Volltext

Verfügbarkeit prüfen

Superior efficacy of St John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298]

BMC medicine, 2006-06, Vol.4 (1), p.14-14, Article 14

2006

Link zum Volltext

Verfügbarkeit prüfen

Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2019-11, Vol.322 (19), p.1887

2019

Link zum Volltext

Verfügbarkeit prüfen

Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial

Lancet neurology, 2020-09, Vol.19 (9), p.727-737

2020

Link zum Volltext

Verfügbarkeit prüfen

Mirtazapine: a review of its clinical efficacy and tolerability

Expert opinion on pharmacotherapy, 2005-04, Vol.6 (4), p.631-641

2005

Link zum Volltext

Verfügbarkeit prüfen

What does the HAMD mean?

Journal of affective disorders, 2013-06, Vol.148 (2), p.243-248

2013

Link zum Volltext

Verfügbarkeit prüfen

Translating the HAM-D into the MADRS and vice versa with equipercentile linking

Journal of affective disorders, 2018-01, Vol.226, p.326-331

2018

Link zum Volltext

Verfügbarkeit prüfen

Nur noch Stiefkind der Psychiatrie?: Klinische Psychopharmakologie

NeuroTransmitter, 2011-11, Vol.22 (S2), p.34-42

Szegedi, Armin

2011

Link zum Volltext

Verfügbarkeit prüfen

What does the MADRS mean? Equipercentile linking with the CGI using a company database of mirtazapine studies

Journal of affective disorders, 2017-03, Vol.210, p.287-293

2017

Link zum Volltext

Verfügbarkeit prüfen

OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo-controlled trial in adult females

International clinical psychopharmacology, 2020-01, Vol.35 (1), p.19

2020

Link zum Volltext

Verfügbarkeit prüfen

Randomized, Double-Blind, Placebo-Controlled Trial of Asenapine Maintenance Therapy in Adults With an Acute Manic or Mixed Episode Associated With Bipolar I Disorder

The American journal of psychiatry, 2018-01, Vol.175 (1), p.71-79

2018

Link zum Volltext

Verfügbarkeit prüfen

Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults

Cephalalgia, 2019-12, Vol.39 (14), p.1753-1761

2019

Link zum Volltext

Verfügbarkeit prüfen

Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients

The journal of clinical psychiatry, 2007-08, Vol.68 (8), p.1195

2007

Link zum Volltext

Verfügbarkeit prüfen

The HTR1B 861G>C receptor polymorphism among patients suffering from alcoholism, major depression, anxiety disorders and narcolepsy

Psychiatry research, 2000-12, Vol.97 (1), p.1-10

2000

Link zum Volltext

Verfügbarkeit prüfen

The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial

Journal of clinical psychopharmacology, 2014-04, Vol.34 (2), p.190-198

2014

Link zum Volltext

Verfügbarkeit prüfen

Effect of Reversal of Neuromuscular Blockade with Sugammadex versus Usual Care on Bleeding Risk in a Randomized Study of Surgical Patients

Anesthesiology (Philadelphia), 2014-11, Vol.121 (5), p.969-977

2014

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis

Headache, 2021-03, Vol.61 (3), p.422-429

2021

Link zum Volltext

Verfügbarkeit prüfen

Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients

The journal of clinical psychiatry, 2009-03, Vol.70 (3), p.344

2009

Link zum Volltext

Verfügbarkeit prüfen

Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications

Cephalalgia, 2021-04, Vol.41 (5), p.546-560

2021

Link zum Volltext

Verfügbarkeit prüfen

Treating major depressive disorder with onabotulinumtoxinA: Safety and efficacy 24 weeks following a single injection session

Toxicon (Oxford), 2018-12, Vol.156, p.S12-S12

2018

Link zum Volltext

Verfügbarkeit prüfen

Asenapine as Adjunctive Treatment for Acute Mania Associated With Bipolar Disorder: Results of a 12-Week Core Study and 40-Week Extension

Journal of clinical psychopharmacology, 2012-02, Vol.32 (1), p.46-55

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 102

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(98)
Mit Volltextzugriff
(84)

Publikationsform

Artikel
(101)
Bücher
(1)

Sprache

Englisch
(100)
Japanisch
(7)
Deutsch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(79)
Science & Technology
(79)
Humans
(78)
Male
(67)
Adult
(66)
Female
(62)
Psychiatry
(61)
Middle Aged
(49)
Biological And Medical Sciences
(44)
Medical Sciences
(44)
Psychology. Psychoanalysis. Psychiatry
(35)
Double-Blind Method
(28)
Psychopathology. Psychiatry
(28)
Treatment Outcome
(28)
Neurosciences & Neurology
(27)
Psychiatric Status Rating Scales
(24)
Clinical Neurology
(21)
Adolescent
(20)
Adult And Adolescent Clinical Studies
(20)
Pharmacology & Pharmacy
(20)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ubrogepant for the Treatment of Migraine

Asenapine for the Acute Treatment of Pediatric Manic or Mixed Episode of Bipolar I Disorder

A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment

Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials

Sollte bereits nach zwei Wochen ein Medikationswechsel erfolgen?

Superior efficacy of St John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298]

Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial

Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial

Mirtazapine: a review of its clinical efficacy and tolerability

What does the HAMD mean?

Translating the HAM-D into the MADRS and vice versa with equipercentile linking

Nur noch Stiefkind der Psychiatrie?: Klinische Psychopharmakologie

What does the MADRS mean? Equipercentile linking with the CGI using a company database of mirtazapine studies

OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo-controlled trial in adult females

Randomized, Double-Blind, Placebo-Controlled Trial of Asenapine Maintenance Therapy in Adults With an Acute Manic or Mixed Episode Associated With Bipolar I Disorder

Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults

Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients

The HTR1B 861G>C receptor polymorphism among patients suffering from alcoholism, major depression, anxiety disorders and narcolepsy

The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial

Effect of Reversal of Neuromuscular Blockade with Sugammadex versus Usual Care on Bleeding Risk in a Randomized Study of Surgical Patients

Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis

Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients

Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications

Treating major depressive disorder with onabotulinumtoxinA: Safety and efficacy 24 weeks following a single injection session

Asenapine as Adjunctive Treatment for Acute Mania Associated With Bipolar Disorder: Results of a 12-Week Core Study and 40-Week Extension

Suchergebnisse filtern